Showing 4751-4760 of 9576 results for "".
- Study: Vagus Nerve Stimulation Improves ETR Symptomshttps://practicaldermatology.com/news/study-vagus-nerve-stimulation-improves-etr-symptoms/2483900/Results from a recent study suggest transcutaneous auricular vagus nerve stimulation (taVNS) could be a viable therapeutic option for patients with erythematotelangiectatic rosacea (ETR). Researchers for the randomized, double-
- Analysis: Ceramide Skincare from Birth May Mitigate Pediatric ADhttps://practicaldermatology.com/news/analysis-ceramide-skincare-from-birth-may-mitigate-pediatric-ad/2483872/A new consensus paper offers clinical recommendations to address the complex interplay of skin barrier dysfunction and SAIGE (Staphylococcus aureus colonization, immunologic, genetic, and environmental) factors in pediatric atopic dermatitis (AD).
- Latino Melanoma Patients Face Barriers to Early Diagnosis and Treatmenthttps://practicaldermatology.com/news/latino-melanoma-patients-face-barriers-to-early-diagnosis-and-treatment/2483846/A new qualitative study published in JAMA Dermatology explored persistent disparities Latino patients face in timely melanoma diagnosis and treatment, despite advances in therapy that have improved survival among non-Hispani
- Accelerated Phenotypic Aging Linked to Increased Mortality With PsOhttps://practicaldermatology.com/news/accelerated-phenotypic-aging-linked-to-increased-mortality-with-pso/2483591/A new analysis of US adult data has found that phenotypic age acceleration (PhenoAge-accel) is associated with increased risk of psoriasis and—when coexisting with the disease—elevated risk of all-cause and cardiovascular disease (CVD) mortality. The study, publishe
- Study: Ruxolitinib Cream Same or Better Than Triamcinolone for Mild to Moderate ADhttps://practicaldermatology.com/news/ruxolitinib-cream-triamcinolone-for-mild-to-moderate-ad/2483574/New analysis of phase 2 data indicates ruxolitinib cream 1.5% may offer comparable or superior efficacy to midpotency corticosteroid triamcinolone 0.1% cream in adult patients with long-standing mild to moderate atopic dermatitis (AD).
- From EADV: Bimekizumab Shows Sustained Efficacy in Plaque Psoriasis and HShttps://practicaldermatology.com/news/from-eadv-bimekizumab-shows-sustained-efficacy-in-plaque-psoriasis-and-hs/2483464/New data presented by UCB at the 2025 European Academy of Dermatology and Venereology (EADV) Congress in Paris showed sustained efficacy and tolerability for BIMZELX® (bimekizumab-bkzx) in both moderate-to-severe hidradenitis suppurativa (HS) and plaque psoriasis. <
- FDA Clears IND for Rubedo’s GPX4 Modulator in Actinic Keratosishttps://practicaldermatology.com/news/fda-clears-ind-for-rubedos-gpx4-modulator-in-actinic-keratosis/2483388/Rubedo Life Sciences has received FDA clearance for a second Investigational New Drug (IND) application for its lead compound RLS-1496, enabling a Phase 1b/2a trial in patients with actinic keratosis to begin in Q4 2025. Accordi
- Galderma to Present Long-Term Nemluvio Data, Global Sensitive Skin Survey at EADV 2025https://practicaldermatology.com/news/galderma-to-present-long-term-nemluvio-data-global-sensitive-skin-survey-at-eadv-2025/2483331/Galderma will present new findings on sensitive skin, as well as long-term data on nemolizumab (Nemluvio®) at the 34th European Academy of Dermatology and Venereology (EADV) Congress, to be held in Paris, September 17–20, 2025, a press statement from the manufactur
- Incyte to Present STOP-HS, TRuE-PN Trials at EADV 2025https://practicaldermatology.com/news/late-breaking-hs-and-pn-data-to-anchor-incytes-eadv-presentations/2483330/Incyte announced that it will present new data from studies throughouts its dermatology pipeline at the 2025 European Academy of Dermatology and Venereology (EADV) Congress in Paris, according to a press release from the manufacturer.
- IL-17 Inhibitors Not Linked to MACE: Analysishttps://practicaldermatology.com/news/il-17-inhibitors-not-linked-to-maces/2483300/Results from a large French case–time–control study revealed no association between the administration of interleukin (IL)-17 receptor A inhibitors and major adverse cardiovascular events (MACE). Researchers used data from mo